GB0119480D0 - Novel compositions - Google Patents

Novel compositions

Info

Publication number
GB0119480D0
GB0119480D0 GBGB0119480.2A GB0119480A GB0119480D0 GB 0119480 D0 GB0119480 D0 GB 0119480D0 GB 0119480 A GB0119480 A GB 0119480A GB 0119480 D0 GB0119480 D0 GB 0119480D0
Authority
GB
United Kingdom
Prior art keywords
novel compositions
nanoparticles
compositions
fibrate
tpgs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0119480.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Jagotec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec AG filed Critical Jagotec AG
Priority to GBGB0119480.2A priority Critical patent/GB0119480D0/en
Publication of GB0119480D0 publication Critical patent/GB0119480D0/en
Priority to JP2003518484A priority patent/JP4721640B2/ja
Priority to US10/486,299 priority patent/US8663693B2/en
Priority to ES02749130T priority patent/ES2321912T3/es
Priority to PCT/GB2002/003687 priority patent/WO2003013474A1/en
Priority to EP02749130A priority patent/EP1414410B1/en
Priority to AT02749130T priority patent/ATE422155T1/de
Priority to DE60231082T priority patent/DE60231082D1/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
GBGB0119480.2A 2001-08-09 2001-08-09 Novel compositions Ceased GB0119480D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0119480.2A GB0119480D0 (en) 2001-08-09 2001-08-09 Novel compositions
JP2003518484A JP4721640B2 (ja) 2001-08-09 2002-08-09 フェノフィブラートのナノ粒子製剤
US10/486,299 US8663693B2 (en) 2001-08-09 2002-08-09 Nanoparticulate formulations of fenofibrate
ES02749130T ES2321912T3 (es) 2001-08-09 2002-08-09 Formulaciones en nanoparticulas de fenofibrato.
PCT/GB2002/003687 WO2003013474A1 (en) 2001-08-09 2002-08-09 Nanoparticulate formulations of fenofibrate
EP02749130A EP1414410B1 (en) 2001-08-09 2002-08-09 Nanoparticulate formulations of fenofibrate
AT02749130T ATE422155T1 (de) 2001-08-09 2002-08-09 Nanopartikelzusammensetzungen enthaltend fenofibrat
DE60231082T DE60231082D1 (de) 2001-08-09 2002-08-09 Nanopartikelzusammensetzungen enthaltend fenofibrat

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0119480.2A GB0119480D0 (en) 2001-08-09 2001-08-09 Novel compositions

Publications (1)

Publication Number Publication Date
GB0119480D0 true GB0119480D0 (en) 2001-10-03

Family

ID=9920132

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0119480.2A Ceased GB0119480D0 (en) 2001-08-09 2001-08-09 Novel compositions

Country Status (8)

Country Link
US (1) US8663693B2 (https=)
EP (1) EP1414410B1 (https=)
JP (1) JP4721640B2 (https=)
AT (1) ATE422155T1 (https=)
DE (1) DE60231082D1 (https=)
ES (1) ES2321912T3 (https=)
GB (1) GB0119480D0 (https=)
WO (1) WO2003013474A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
AU2003245313A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
CN1829499A (zh) * 2003-05-29 2006-09-06 格利康科技集团有限责任公司 稳定并控制传递(－)－羟基柠檬酸的方法和组合物
JP2008514714A (ja) * 2004-09-30 2008-05-08 イーストマン ケミカル カンパニー 有意な流出阻害を示さない、親油性薬物を可溶化するビタミンｅｔｐｇｓ分子を含む医薬製剤及びこのような医薬製剤の使用
JP5112669B2 (ja) * 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
US20070128289A1 (en) * 2005-12-07 2007-06-07 Zhao Jonathon Z Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases
WO2008002568A2 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US20080161594A1 (en) * 2006-12-29 2008-07-03 Industrial Technology Research Institute Method for fabricating nanoparticles containing fenofibrate
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
JP5711671B2 (ja) 2009-02-23 2015-05-07 ナノルクス、インコーポレイテッドＮａｎｏｒｘ，Ｉｎｃ． ポリコサノールナノ粒子
US8888736B2 (en) 2010-04-30 2014-11-18 H R D Corporation High shear application in medical therapy
WO2011139479A2 (en) 2010-04-30 2011-11-10 H R D Corporation High shear application in drug delivery
CA2844073C (en) 2010-08-23 2015-10-13 NanoRx, Inc. Policosanol nanoparticles
GB201118181D0 (en) * 2011-10-21 2011-12-07 Jagotec Ag Pharmaceutical compositions
BR112015001838B1 (pt) * 2012-07-27 2022-10-25 Izumi Technology, Llc Composição de inibidor de efluxo
CN104903494B (zh) * 2012-09-21 2017-11-03 瑞奥可塞恩探索集团有限公司 用于电解液体的电池
US11285115B2 (en) 2013-02-28 2022-03-29 Ramot At Tel-Aviv University Ltd. Peptide-based hydrogel particles and uses thereof
CN105218370A (zh) * 2014-06-10 2016-01-06 无锡康福特药物科技有限公司 一种贝特类降脂药物的超微粉体及其制备方法
PL3833335T3 (pl) * 2019-07-31 2023-01-02 Intas Pharmaceuticals Ltd. Kompozycja farmaceutyczna zawierająca inhibitory reduktazy HMG-CoA i fenofibrat
PL3928772T3 (pl) 2020-06-26 2024-10-07 Algiax Pharmaceuticals Gmbh Kompozycja nanocząstkowa
US20230398234A1 (en) * 2020-10-28 2023-12-14 Mydecine Innovations Group Inc. Novel fungal compoind formulations and their therapeutic methods of use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
DE19800250A1 (de) 1997-01-13 1998-08-06 Winter Cvd Technik Gmbh Schleifkörper
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
WO1999029300A1 (en) * 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations
FR2774591B1 (fr) 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
FR2776191B1 (fr) 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
CA2335472C (en) 1998-06-19 2008-10-28 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
FR2783421B1 (fr) 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
EP1133280A1 (en) 1998-11-20 2001-09-19 RTP Pharma Inc. Method of preparing stable suspensions of insoluble microparticles
US6180138B1 (en) * 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2795961B1 (fr) 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US6251426B1 (en) * 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
ATE296091T1 (de) * 1999-09-21 2005-06-15 Skyepharma Canada Inc Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US6464511B1 (en) 1999-11-17 2002-10-15 Advantest Corporation IC socket and IC tester
FR2803203B1 (fr) 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate

Also Published As

Publication number Publication date
JP2005509596A (ja) 2005-04-14
EP1414410A1 (en) 2004-05-06
ATE422155T1 (de) 2009-02-15
ES2321912T3 (es) 2009-06-15
WO2003013474A1 (en) 2003-02-20
JP4721640B2 (ja) 2011-07-13
US20050095297A1 (en) 2005-05-05
US8663693B2 (en) 2014-03-04
DE60231082D1 (de) 2009-03-19
EP1414410B1 (en) 2009-02-04

Similar Documents

Publication Publication Date Title
GB0119480D0 (en) Novel compositions
WO2005002542A3 (en) Nanoparticulate meloxican formulations
BRPI0410767A (pt) formulações farmacêuticas de partìcula pequena de agentes antiataque e antidemência e agentes imunossupressores
WO2005035441A3 (en) Subtituted fullerene compositions and their use as antioxydants
MY142960A (en) Cholesteric monolayers and monolayer pigments with particular properties, their production and use
WO2004022637A3 (en) Nanocomposites
CY1113036T1 (el) Φαρμακοτεχνικες μορφες νανοσωματιδιων μεγεστρολης
WO2004084453A3 (en) METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES
DE602004006994D1 (en) 3-aryloxy und 3-heteroaryloxy substituierte benzo(b) thiophene als therapeutische wirkstoffe mit pi3k aktivität
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
BR0214679A (pt) Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
IL177394A0 (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2002047606A3 (fr) Compositions cosmetiques transparentes ou translucides colorees par des pigments
EA200401556A1 (ru) Препараты на основе наночастиц фибрата
BR0014087A (pt) Composições com pérolas de caroteno - xantofila estáveis e métodos de uso
FR2847812B1 (fr) Composition cosmetique comprenant des nanoparticules fluorescentes comme pigments
ATE411010T1 (de) Topische nanopartikel-spironolacton-formulierung
BRPI0408848A (pt) formulações orais de cladribine
WO2007064842A3 (en) Synthesis of chlorins and phorbines with enhanced red spectral features
WO2005025491A3 (en) Water-soluble polyamioamides as sunscreen agents
WO2007146943A3 (en) Nanoparticulate kinase inhibitor formulations
MA29492B1 (fr) Formulations stables de nanoparticules
WO2002102391A3 (en) Composition comprising nanoparticulate spironolactone
UA95088C2 (ru) Композиция, которая содержит наночастички связанные с биосовместимым полимером противоракового агента и снижает аллопецию при химиотерапии, способ ее получения
DE50310932D1 (de) Sporopollenin enthaltende lösliche zusammensetzung und verwendung

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)